Results 61 to 70 of about 4,127 (170)

Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025

Cancer Innovation, Volume 5, Issue 2, April 2026.
This review summarizes key breakthrough advances in hepatocellular carcinoma (HCC) reported in 2025 and presents a multidisciplinary management framework for HCC, integrating early diagnosis, microenvironment insights, and comprehensive therapeutic strategies spanning minimally invasive surgery, locoregional interventions, and systemic pharmacotherapy.
Bo Hu, Qiang Gao
wiley   +1 more source

Predictors of Hepatic Decompensation after Yttrium90 Transarterial Radioembolization—Optimizing Patient Selection

Journal of Clinical Interventional Radiology ISVIR
Purpose Yttrium 90 (Y90) transarterial radioembolization (TARE) is effective for unresectable hepatocellular carcinoma (HCC) or to bridge/downstage before transplant; however, optimal patient selection is not well-described. This study aims to
Amelia Wong, Shirley Cheng, Anthony Herrera, Linda Wong   +3 more
doaj   +1 more source

Liver Transplantation After Combination Therapy Based on Immune Checkpoint Inhibitors: A Multicenter Retrospective Study of Safety and Efficacy

Organ Medicine, Volume 3, Issue 1, Page 12-19, March 2026.
This multicenter retrospective study assessed preoperative immune checkpoint inhibitor (ICI) therapy in 17 hepatocellular carcinoma patients undergoing liver transplantation. All received at least one cycle of ICI‐based combination therapy before transplant and achieved a 76.5% objective response rate.
Huanquan Chen, Tianxing Dai, Jie Gao, Chuanjiang Li, Huanwei Chen, Feiwen Deng, Nan Ma, Guoying Wang   +7 more
wiley   +1 more source

Superselective transarterial radioembolization for the treatment of hepatocellular carcinoma

International Journal of Gastrointestinal Intervention, 2021
Superselective transarterial radioembolization (TARE) refers the delivery of Y90 at the tumor-feeding segmental or subsegmental arteries. The purpose of TARE would be delivering high dose in the tumor while saving as much normal parenchyma as possible. This concept is similar to the radiation segmentectomy.
openaire   +4 more sources

Transarterial Infusion of Pembrolizumab Plus TACE for Liver Metastases of Melanoma

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background Melanoma hepatic metastases demonstrate limited responsiveness to conventional systemic immune checkpoint blockade therapy, primarily attributed to the hepatic microenvironment's immunosuppressive characteristics. To our knowledge, this is the first reported case describing selective hepatic arterial infusion of pembrolizumab ...
Shahram Akhlaghpoor, Hamidreza Rouientan
wiley   +1 more source

Emerging Role of MRI‐Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review

Journal of Magnetic Resonance Imaging, Volume 63, Issue 1, Page 79-97, January 2026.
ABSTRACT Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer, with significant variability in patient outcomes even within the same stage according to the Barcelona Clinic Liver Cancer staging system. Accurately predicting patient prognosis and potential treatment response prior to therapy initiation is crucial for ...
Feng Che, Jing Zhu, Qian Li, Hanyu Jiang, Yi Wei, Bin Song   +5 more
wiley   +1 more source

Transarterial Radioembolization (TARE) Agents beyond ⁹⁰Y-Microspheres

BioMed Research International, 2018
Liver malignancies, either primary tumours (mainly hepatocellular carcinoma and cholangiocarcinoma) or secondary hepatic metastases, are a major cause of death, with an increasing incidence. Among them, hepatocellular carcinoma (HCC) presents with a dark prognosis because of underlying liver diseases and an often late diagnosis.
Bouvry, C., Palard, X., Edeline, J., Ardisson, V., Loyer, P., Garin, E., Lepareur, Nicolas   +6 more
openaire   +4 more sources

Hydrogel Microspheres for Biomedical Applications

Small Science, Volume 6, Issue 1, January 2026.
Hydrogel microspheres (HMs) play pivotal roles in biomedical applications, such as drug delivery, cell culture, regenerative medicine, wound healing, and tumor immunity. This review focuses on the latest findings to provide a more comprehensive understanding of HMs for biomedical applications.
Yingkang Huang, Xi Zhu, Jinhong Zhou, Henan Li, Wei Zhang, Danyang Shen, Ziyan Huang, Tianbo Zhang, Lin Zhuang, Lei Qin, Xiaofeng Xue, Yunjie Lu   +11 more
wiley   +1 more source

Five Advances in the Last 50 Years: Liver Malignancies

World Journal of Surgery, Volume 50, Issue 8, Page 2116-2120, August 2026.
Alex B. Blair, Timothy M. Pawlik
wiley   +1 more source

Risk Group Stratification for True Early Recurrence After Ablation for Hepatomas

Canadian Journal of Gastroenterology and Hepatology, Volume 2026, Issue 1, 2026.
Background Hepatocellular carcinoma (HCC) is a lethal cancer. Early recurrence, i.e., recurrence within two years of curative treatment, is a major determinant of ultimate survival. Materials and Methods We included 625 patients with newly diagnosed early‐stage HCC, i.e., Barcelona Clinic Liver Cancer (BCLC) Stage 0 or A, and Child–Pugh Class A liver ...
Yi-Hao Yen, Kwong-Ming Kee, Chao-Hung Hung, Chien-Hung Chen, Tsung-Hui Hu, Jing-Houng Wang, Sheng-Nan Lu, Neetu Rawal   +7 more
wiley   +1 more source